GSK To Buy Nuvalent
GSK To Buy Nuvalent adds three late-stage lung-cancer candidates, two under FDA review in 2026, and focuses investor attention on earnings and pipeline.
KEY TAKEAWAYS
- GSK agreed to acquire Nuvalent for approximately $10.6 billion.
- Deal expected to boost revenue growth from 2027 and be accretive to core EPS in 2029.
- Adds three advanced lung-cancer candidates, two under FDA review for possible 2026 approvals.
HIGH POTENTIAL TRADES SENT DIRECTLY TO YOUR INBOX
Add your email to receive our free daily newsletter. No spam, unsubscribe anytime.
GSK plc said on June 9, 2026, that it agreed to acquire U.S. cancer-drug developer Nuvalent Inc., adding three advanced lung-cancer candidates, two of which are under FDA review for possible approval in 2026.
Deal Terms and Financial Outlook
GSK agreed to acquire Nuvalent in an all-cash transaction valued at approximately $10.6 billion, marking its largest deal in more than a decade. GSK is a U.K.-based global biopharmaceutical company listed in London and on the New York Stock Exchange. Nuvalent, listed in the U.S. and based in Cambridge, Massachusetts, is a clinical-stage developer focused on precision targeted cancer therapies.
Earlier reports indicated GSK was in talks to buy Nuvalent for more than $9 billion, with a valuation range of $9 billion to $10 billion before the definitive agreement.
The acquisition adds three advanced lung-cancer drug candidates to GSK’s portfolio, two of which are currently under review by the U.S. Food and Drug Administration for potential approval in 2026. GSK expects the deal to contribute to revenue growth starting in 2027, be accretive to core operating profit in 2027, and accretive to core earnings per share in 2029, incorporating cost synergies and portfolio reprioritization. These metrics are stated on a core (non-GAAP) basis, which typically excludes restructuring and one-time items.
Nuvalent specializes in precision targeted therapies for non-small-cell lung cancer, with lead programs including a candidate named neladectib. External analysts have projected some of these assets could generate multi-billion-dollar peak sales. GSK positions the acquisition as a way to accelerate its oncology expansion, providing near-term regulatory catalysts and a multi-year earnings timeline.
Strategically, the deal represents a shift from GSK’s recent pattern of smaller acquisitions, signaling a stronger commitment to building its oncology franchise. The company’s integration and commercialization decisions will determine whether these programs deliver the expected sales and profit contributions.
